Jul 15, 2024 6:00am EDT Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study
Jul 1, 2024 7:00am EDT Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors